Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Virginia: - Augusta Health Center for Cancer and Blood Disorders — Fishersville, Virginia
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Phase 3 Recruiting Network
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …
Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- Children's Hospital of The King's Daughters — Norfolk, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Phase 3 Recruiting Industry
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05580562
Sites in Virginia: - Inova Schar Cancer Institute — Fairfax, Virginia
- Children's Hospital of The King's Daughter — Norfolk, Virginia
Phase 3 Recruiting Industry
This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) …
Sponsor: Nuvation Bio Inc.
NCT ID: NCT05303519
Sites in Virginia: - UVA Health, Emily Couric Clinical Cancer Cente — Charlottesville, Virginia
- Inova Schar Cancer Institute — Fairfax, Virginia
Phase 3 Recruiting Industry
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together…
Sponsor: NovoCure GmbH
NCT ID: NCT06556563
Sites in Virginia: - Inova Schar Cancer Institute — Fairfax, Virginia
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved,…
Sponsor: InSightec
NCT ID: NCT05317858
Sites in Virginia: - Johnston Willis Hospital — Richmond, Virginia
Phase 2 Recruiting Network
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …
Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- Children's Hospital of The King's Daughters — Norfolk, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
- Carilion Children's — Roanoke, Virginia
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy alone (temozo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05432804
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Phase 1, Phase 2 Recruiting Industry
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT04094610
Sites in Virginia: - Children's Hospital of Richmond at VCU — Richmond, Virginia
Phase 2 Recruiting Academic/Other
This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (a…
Sponsor: Patrick Wen, MD
NCT ID: NCT02977780
Sites in Virginia: - University of Virginia Health System — Charlottesville, Virginia
Phase 1, Phase 2 Recruiting Industry
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurr…
Sponsor: AstraZeneca
NCT ID: NCT05417594
Sites in Virginia: - Research Site — Richmond, Virginia
Phase 2 Recruiting Academic/Other
This phase IIa trial studies how well dendritic cell vaccines against Her2/Her3 and pembrolizumab work for the treatment of triple negative breast cancer or HER2+ breast cancer or HER+ Breast cancer that has spread to the brain (brain meta…
Sponsor: Roswell Park Cancer Institute
NCT ID: NCT04348747
Sites in Virginia: - University of Virginia Comprehensive Cancer Center — Charlottesville, Virginia
Phase 1 Recruiting NIH
This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06860594
Sites in Virginia: - VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Phase 1 Recruiting Industry
The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.
Sponsor: A2A Pharmaceuticals Inc.
NCT ID: NCT06136884
Sites in Virginia: - Next Oncology -Virginia — Fairfax, Virginia
Phase 1 Recruiting Academic/Other
Patients diagnosed with glioblastoma (GBM) are faced with limited treatment options. This pilot study will evaluate the safety and feasibility of combining an investigational drug called 5-ALA with neuronavigation-guided low-intensity focu…
Sponsor: Shayan Moosa, MD
NCT ID: NCT06039709
Sites in Virginia: - University of Virginia — Charlottesville, Virginia
Phase 1 Recruiting Academic/Other
This is a phase 1 study for patients with newly diagnosed MGMT unmethylated IDH wild-type glioblastoma utilizing autologous activated T-cells armed with bispecific antibody (EGFR-BATs) that recognize the tumor. The investigators hypothesiz…
Sponsor: University of Virginia
NCT ID: NCT07343986
Sites in Virginia: - University of Virginia — Charlottesville, Virginia
EARLY Phase 1 Recruiting Academic/Other
Postoperative pain is prevalent after intracranial surgery. Patients undergoing craniotomy are typically managed with short acting opioids to enable early and reliable post-operative neurological exam as well as avoid the risk of respirato…
Sponsor: University of Virginia
NCT ID: NCT06810336
Sites in Virginia: - University of Virginia — Charlottesville, Virginia
Recruiting Industry
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
Sponsor: GT Medical Technologies, Inc.
NCT ID: NCT04427384
Sites in Virginia: - INOVA Health — Fairfax, Virginia
NA Recruiting Academic/Other
The goal of this clinical trial is to learn about the acceptability and feasibility of Cognitive Strategies, Mindfulness, and Rehabilitation Therapy (C-SMART) and Brain health Education and Wellness (BE Well) in adults with brain tumors an…
Sponsor: Virginia Commonwealth University
NCT ID: NCT07224503
Sites in Virginia: - Virginia Commonwealth University — Richmond, Virginia